BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

18060

543960

CONCORDBIO

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

CONCORD BIOTECH LIMITED performance

Today’s low

Today’s high

₹ 1510.10 ₹ 1583.00
₹ 1518.60

52 week low

52 week high

₹ 1327.05 ₹ 2664.00
₹ 1518.60

Open Price

₹ 1583.00

Prev. Close

₹ 1557.80

Volume (Shares)

100275.00

Total traded value

₹ 1522.77

Upper Circuit

₹ 1869.30

Lower Circuit

₹ 1246.30

info

CONCORD BIOTECH LIMITED Share Price Update

As of the latest trading session, CONCORD BIOTECH LIMITED share price is currently at ₹ 1518.6, which is down by ₹ -39.20 from its previous closing. Today, the stock has fluctuated between ₹ 1510.10 and ₹ 1583.00. Over the past year, CONCORD BIOTECH LIMITED has achieved a return of -5.61 %. In the last month alone, the return has been -6.32 %. Read More...

CONCORD BIOTECH LIMITED fundamentals


  • Market cap (Cr)

    15,887.02

  • P/E Ratio (TTM)

    49.65

  • Beta

    0.91

  • Book Value / share

    152.04

  • Return on equity

    21.63%

  • EPS (TTM)

    31.38

  • Dividend yield

    0.56%

  • Net profit/quarter (Cr)

    74.09

info icon alternate text
  • Market cap (Cr)

    15,849.36

  • P/E Ratio (TTM)

    49.65

  • Beta

    0.90

  • Book Value / share

    152.04

  • Return on equity

    21.63%

  • EPS (TTM)

    31.38

  • Dividend yield

    0.56%

  • Net profit/quarter (Cr)

    74.09

info icon alternate text

CONCORD BIOTECH LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 244.22
Operating Expense 159.63
Net Profit 74.09
Net Profit Margin (%) 30.33
Earnings Per Share (EPS) 7.08
EBITDA 112.67
Effective Tax Rate (%) 25.40
Particulars SEP 2024 (Values in Cr)
Revenue 310.18
Operating Expense 186.92
Net Profit 98.70
Net Profit Margin (%) 31.82
Earnings Per Share (EPS) 9.43
EBITDA 146.70
Effective Tax Rate (%) 25.95
Particulars JUN 2024 (Values in Cr)
Revenue 215.80
Operating Expense 147.94
Net Profit 58.24
Net Profit Margin (%) 26.98
Earnings Per Share (EPS) 5.57
EBITDA 91.59
Effective Tax Rate (%) 25.49
Particulars MAR 2024 (Values in Cr)
Revenue 318.97
Operating Expense 198.86
Net Profit 97.21
Net Profit Margin (%) 30.47
Earnings Per Share (EPS) 9.29
EBITDA 145.10
Effective Tax Rate (%) 25.74
Particulars DEC 2023 (Values in Cr)
Revenue 240.80
Operating Expense 148.90
Net Profit 74.55
Net Profit Margin (%) 30.95
Earnings Per Share (EPS) 7.13
EBITDA 114.12
Effective Tax Rate (%) 25.50
Particulars MAR 2024 (Values in Cr)
Revenue 1016.94
Operating Expense 641.52
Net Profit 304.73
Net Profit Margin (%) 29.96
Earnings Per Share (EPS) 29.13
EBITDA 465.33
Effective Tax Rate (%) 25.52
Particulars MAR 2023 (Values in Cr)
Revenue 853.17
Operating Expense 568.42
Net Profit 238.13
Net Profit Margin (%) 27.91
Earnings Per Share (EPS) 22.76
EBITDA 378.59
Effective Tax Rate (%) 25.59
Particulars MAR 2022 (Values in Cr)
Revenue 712.93
Operating Expense 495.19
Net Profit 178.57
Net Profit Margin (%) 25.04
Earnings Per Share (EPS) 187.76
EBITDA 296.69
Effective Tax Rate (%) 25.95
Particulars MAR 2021 (Values in Cr)
Revenue 616.94
Operating Expense 317.59
Net Profit 235.33
Net Profit Margin (%) 38.14
Earnings Per Share (EPS) 247.40
EBITDA 341.36
Effective Tax Rate (%) 24.85
Particulars MAR 2024 (Values in Cr)
Book Value / Share 145.93
ROE % 21.88
ROCE % 29.05
Total Debt to Total Equity 0.01
EBITDA Margin 46.15
Particulars MAR 2023 (Values in Cr)
Book Value / Share 123.31
ROE % 20.06
ROCE % 26.27
Total Debt to Total Equity 0.04
EBITDA Margin 44.68
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1159.99
ROE % 16.64
ROCE % 21.59
Total Debt to Total Equity 0.07
EBITDA Margin 41.20
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1050.80
ROE % 26.60
ROCE % 32.85
Total Debt to Total Equity 0.08
EBITDA Margin 55.42
Particulars MAR 2020 (Values in Cr)
Book Value / Share 809.87
ROE % 19.69
ROCE % 23.23
Total Debt to Total Equity 0.07
EBITDA Margin 41.50
Particulars MAR 2024 (Values in Cr)
Book Value / Share 145.80
ROE % 21.63
ROCE % 28.81
Total Debt to Total Equity 0.01
EBITDA Margin 45.82
Particulars MAR 2023 (Values in Cr)
Book Value / Share 123.50
ROE % 19.85
ROCE % 26.05
Total Debt to Total Equity 0.04
EBITDA Margin 44.45
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1164.13
ROE % 16.95
ROCE % 21.86
Total Debt to Total Equity 0.07
EBITDA Margin 41.71
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1051.11
ROE % 26.59
ROCE % 32.82
Total Debt to Total Equity 0.08
EBITDA Margin 55.39
Particulars MAR 2020 (Values in Cr)
Book Value / Share 809.71
ROE % 20.86
ROCE % 25.21
Total Debt to Total Equity 0.04
EBITDA Margin 41.47
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 47.02
Total Assets 1700.70
Total Liabilities 1700.70
Total Equity 1526.64
Share Outstanding 104616204
Price to Book Ratio 10.44
Return on Assets (%) 18.11
Return on Capital (%) 20.1
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 43.44
Total Assets 1513.98
Total Liabilities 1513.98
Total Equity 1290.00
Share Outstanding 104616204
Price to Book Ratio 0.00
Return on Assets (%) 15.85
Return on Capital (%) 18.17
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 88.93
Total Assets 1312.79
Total Liabilities 1312.79
Total Equity 1103.22
Share Outstanding 9510564
Price to Book Ratio 0.00
Return on Assets (%) 13.32
Return on Capital (%) 15.03
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.58
Total Assets 940.72
Total Liabilities 940.72
Total Equity 770.23
Share Outstanding 9510564
Price to Book Ratio 0.00
Return on Assets (%) 17.97
Return on Capital (%) 20.99
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 47.02
Total Assets 1699.31
Total Liabilities 1699.31
Total Equity 1525.25
Share Outstanding 104616204
Price to Book Ratio 10.44
Return on Assets (%) 17.93
Return on Capital (%) 19.9
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 43.44
Total Assets 1514.64
Total Liabilities 1514.64
Total Equity 1291.98
Share Outstanding 104616204
Price to Book Ratio 0.00
Return on Assets (%) 15.72
Return on Capital (%) 18
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 88.93
Total Assets 1313.45
Total Liabilities 1313.45
Total Equity 1107.16
Share Outstanding 9510564
Price to Book Ratio 0.00
Return on Assets (%) 13.59
Return on Capital (%) 15.29
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 60.81
Total Assets 1182.84
Total Liabilities 1182.84
Total Equity 999.67
Share Outstanding 9510564
Price to Book Ratio 0.00
Return on Assets (%) 19.89
Return on Capital (%) 21.67
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.58
Total Assets 940.57
Total Liabilities 940.57
Total Equity 770.08
Share Outstanding 9510564
Price to Book Ratio 0.00
Return on Assets (%) 17.96
Return on Capital (%) 20.97
Particulars MAR 2024 (Values in Cr)
Net Income 412.56
Cash from Operations 368.81
Cash from Investing -154.60
Cash from Financing -99.21
Net change in Cash 11.64
Free Cash Flow 454.50
Particulars MAR 2023 (Values in Cr)
Net Income 322.01
Cash from Operations 316.27
Cash from Investing -157.95
Cash from Financing -85.21
Net change in Cash 2.83
Free Cash Flow 461.36
Particulars MAR 2022 (Values in Cr)
Net Income 237.51
Cash from Operations 268.25
Cash from Investing -111.78
Cash from Financing -100.16
Net change in Cash -4.47
Free Cash Flow 423.76
Particulars MAR 2020 (Values in Cr)
Net Income 213.63
Cash from Operations 204.19
Cash from Investing -113.92
Cash from Financing -42.51
Net change in Cash -1.35
Free Cash Flow 204.19
Particulars MAR 2024 (Values in Cr)
Net Income 409.19
Cash from Operations 368.81
Cash from Investing -154.60
Cash from Financing -99.21
Net change in Cash 11.64
Free Cash Flow 454.50
Particulars MAR 2023 (Values in Cr)
Net Income 320.05
Cash from Operations 316.27
Cash from Investing -157.95
Cash from Financing -85.21
Net change in Cash 2.83
Free Cash Flow 461.36
Particulars MAR 2022 (Values in Cr)
Net Income 241.15
Cash from Operations 268.25
Cash from Investing -111.78
Cash from Financing -100.16
Net change in Cash -4.47
Free Cash Flow 423.76
Particulars MAR 2021 (Values in Cr)
Net Income 313.16
Cash from Operations 241.98
Cash from Investing -195.20
Cash from Financing 31.12
Net change in Cash 2.73
Free Cash Flow 446.16
Particulars MAR 2020 (Values in Cr)
Net Income 213.48
Cash from Operations 204.04
Cash from Investing -113.77
Cash from Financing -42.51
Net change in Cash -1.35
Free Cash Flow 204.04
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

CONCORD BIOTECH LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1518.60 -2.51 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 1595.20
  • 26 Days 1662.70
  • 10 Days 1624.80
  • 50 Days 1729.00
  • 12 Days 1631.30
  • 100 Days 1813.70
  • 20 Days 1649.20
  • 200 Days 1802.00
1561.80 PIVOT

First Support

1534.90

First Resistance

1580.20

Second Support

1516.50

Second Resistance

1607.10

Third Support

1489.60

Third Resistance

1625.50

RSI

37.65

ADX

18.65

MACD

-31.37

Williams % R

-92.37

Commodity Channel Index (CCI)

-138.24

Date

2025-04-29

Week

45282.00

Same Day

44206.00

Month

39655.00

1 Year

0.91

3 Year

0.77

Over 1 Month

-6.32%

down

Over 1 Year

-5.61%

down

Over 3 Months

-24.06%

down

Over 3 Years

0.00%

down

Over 6 Months

-14.43%

down

Over 5 Years

0.00%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

CONCORD BIOTECH LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
37.41%
Promoter Holdings
44.08%
FII
9.35%
DII
9.15%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Sudhir Vaid 3.0169524E7 (28.84%) Shareholding of Promoter and Promoter Group
Manju Vaid 9987636.0 (9.55%) Shareholding of Promoter and Promoter Group
Aryaman Jhunjhunwaladiscretionary Trust 8399754.0 (8.03%) Public Shareholding
Nishtha Jhunjhunwaladiscretionary Trust 8399732.0 (8.03%) Public Shareholding
Aryavir Jhunjhunwala Discretionary Trust 8399754.0 (8.03%) Public Shareholding
Sudman Consultants Llp 4752000.0 (4.54%) Shareholding of Promoter and Promoter Group
Government Pension Fund Global 3122544.0 (2.98%) Public Shareholding
1575773 Ontario Inc 2092325.0 (2.0%) Public Shareholding
Amal Parikh 2023219.0 (1.93%) Public Shareholding
Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund 1620908.0 (1.55%) Public Shareholding
Axis Max Life Insurance Limited A/c Reversionary Bonus Participating - Equity 1617520.0 (1.55%) Public Shareholding
Ravindra Raichand Dharamshi 1406432.0 (1.34%) Public Shareholding
Chanakya Corporate Services Private Limited 1163833.0 (1.11%) Public Shareholding
Hsbc Small Cap Fund 1067966.0 (1.02%) Public Shareholding
Ankur Sudhir Vaid 586520.0 (0.56%) Shareholding of Promoter and Promoter Group
Vaid Megha Ankur 547008.0 (0.52%) Shareholding of Promoter and Promoter Group
Sonal Kumra 73920.0 (0.07%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

CONCORD BIOTECH LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Jun 2024 8.75 Final 22 Jun 2024 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

CONCORD BIOTECH LIMITED Share Price

Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC.

The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat.

In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid.

In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat.
It set up a joint venture in Japan to grow business in 2018.

In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg.

In 2020, Mycophenolate Sodium Tablets got launched in the US market.

The Company added a new manufacturing unit at Limbasi, which commenced operations in July, 2021.

As of March 31, 2022, the Company had 6 fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities.

In August 2023, Company made an Initial Public Offer by issuing 20,925,652 Equity Shares aggregating to Rs 1551 Crores through Offer for Sale.

The Company has launched 21 new formulations products in 2024.

Parent organization Indian Private
NSE symbol CONCORDBIO
Founded 1984
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Concord Biotech Ltd?

Answer Field

The share price of Concord Biotech Ltd for NSE is ₹ 1518.6 and for BSE is ₹ 1515.

What is the Market Cap of Concord Biotech Ltd?

Answer Field

The market cap of Concord Biotech Ltd for NSE is ₹ 1,58,87.02 Cr. and for BSE is ₹ 1,58,49.36 Cr. as of now.

What is the 52 Week High and Low of Concord Biotech Ltd?

Answer Field

The 52 Week High and Low of Concord Biotech Ltd for NSE is ₹ 2664.00 and ₹ 1327.05 and for BSE is ₹ 2658.00 and ₹ 1326.90.

How to Buy Concord Biotech Ltd share?

Answer Field

You can trade in Concord Biotech Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Concord Biotech Ltd?

Answer Field

The 1 year returns on the stock has been -5.61%.

What is the Current Share Price of Concord Biotech Ltd?

Answer Field

Concord Biotech Ltd share price is for NSE ₹ 1518.6 & for BSE ₹ 1515 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Concord Biotech Ltd Share?

Answer Field

The market cap of Concord Biotech Ltd for NSE ₹ 1,58,87.02 & for BSE ₹ 1,58,49.36 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Concord Biotech Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Concord Biotech Ltd share is 49.65.

What is the PB ratio of Concord Biotech Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Concord Biotech Ltd share is 152.04.

How to Buy Concord Biotech Ltd Share?

Answer Field

You can trade in Concord Biotech Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Concord Biotech Ltd Share on Bajaj Broking App?

Answer Field

To buy Concord Biotech Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Concord Biotech Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|